Open access
Open access
Powered by Google Translator Translator

RCT: In patients with Parkinson disease uncontrolled with Levodopa, MAO-B inhibitors or dopamine agonists as adjuvant therapies were associated with better patient-rated quality of life compared to COMT inhibitors.

14 Jan, 2022 | 08:15h | UTC

Long-term Effectiveness of Adjuvant Treatment With Catechol-O-Methyltransferase or Monoamine Oxidase B Inhibitors Compared With Dopamine Agonists Among Patients With Parkinson Disease Uncontrolled by Levodopa Therapy: The PD MED Randomized Clinical Trial – JAMA Neurology

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.